Navigation Links
Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
Date:7/7/2010

any expects additional U.S. and European patent issuances related to the Zamore portfolio in the coming months.

"This latest in a series of related patent issuances continues to highlight the significant value of the groundbreaking Zamore patent families.  For the second time in the past month, we have strengthened our rapidly expanding RNAi IP position with a key patent issuance in the area of structural modification technology," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "Whereas our last patent provided key guidance in enhancing the desired silencing activity of RNAi agents, this latest patent covers the equally valuable ability to minimize the undesired off-target silence activity of RNAi agents."

Silence Therapeutics is executing a proactive strategy to continue to build and strengthen a diverse and competitive intellectual property portfolio that provides the company and its partners with a strong proprietary position in the RNAi therapeutics space.  The company believes that it will continue to make significant progress in these efforts throughout 2010 as it expects a number of additional valuable RNAi patents to be issued in both the United States and Europe during the year.  This consistent and meaningful IP portfolio growth reinforces Silence's belief that the company can sustain its position as a preferred partner in RNAi therapeutics. At present, Silence's global patent portfolio contains issued patents and pending applications covering strategic areas of RNAi therapeutic development including multiple proprietary siRNA delivery technologies, potent siRNA sequences specific for high-value disease targets and key RNAi sequence and chemical modifications.

About Silence Therapeutics plc (

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Silence Therapeutics Announces Successful Opposition of Glover Patent
4. Organizational Changes at Silence Therapeutics
5. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
6. Silence Therapeutics Patent Update
7. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
8. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
9. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
10. Silence Therapeutics Appoints New Vice President of Research
11. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is seeking ... stem cells for dogs with osteoarthritis. Dr. McCarthy has ... clinical stem cell therapy for 7 years. The ultimate ... single injection of donor stem cells into one or ... inflammation in the treated joints. , Candidates for ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... venture capital in more deals in 2006, but the improvement ... Ernst & Young, LLP and Dow Jones ... in 2006, including a $12 .5 million round by ... for a total of $58.47 million. The total, up from ...
... Lance Armstrong is a unique phenomenon. He's a talented athlete, ... league by himself. Or is he? , ,As many people know, ... National Center for Health Statistics report released by the ... the second year in a row. , ,Cancer patients as political ...
... director of technology programs for the University of Wisconsin-Madison, is ... he demonstrates in Part II of this interview. In ... In Part II (below), he addresses creating a culture of ... also is a featured speaker at the Fusion 2007 ...
Cached Biology Technology:Wisconsin fares slightly better in venture capital chase 2Wisconsin fares slightly better in venture capital chase 3Lance Armstrong and the future of cancer care 2Lance Armstrong and the future of cancer care 3Lance Armstrong and the future of cancer care 4Lance Armstrong and the future of cancer care 5
(Date:10/14/2014)... JOLLA, CA – October 14, 2014 – Scientists from ... million from the National Institutes of Health (NIH) to ... prevalent virus-induced hemorrhagic fever disease in Africa. The study ... and why some patients die, while others survive the ... to understand the basic mechanism of how Lassa fever ...
(Date:10/14/2014)... team of researchers, led by the Chinese Academy of ... Nature Genetics a brief genomic history of tomato ... tomato plant. , The C.M. Rick Tomato Genetics Resource ... this study by providing seed of both cultivated tomato ... builds on the first tomato genome sequence completed just ...
(Date:10/14/2014)... October 14, 2014 – Over the past decades, we ... institutions to meet the needs of infants for social ... these infants to thrive. , Infancy and ... of the cortex. A generation of research suggests that ... cortical development and cognitive function. In contrast, deprivation and ...
Breaking Biology News(10 mins):Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2Institutional rearing may increase risk attention-deficit disorder 2
... that links global warming to the recent extinction of ... evidence of a large phenomena that may affect broad ... researchers at Oregon State University. , A study being ... that global climate change created favorable conditions for a ...
... Assertive and even aggressive human behavior could explain why ... downward trend in close encounters with the oceanic predators, ... precautions and in-your-face responses to confrontations with sharks went ... attacks from 65 in 2004 to 58 in 2005 ...
... Very thin but hardy, unblemished skin and slow developing ... hatched Antarctic notothenioids, a group of fish whose adults ... in their blood. , Such adaptations are important, researchers ... larval fish of at least two species of notothenioids ...
Cached Biology News:Extinctions linked to climate change 2Extinctions linked to climate change 3World shark attacks dipped in 2005, part of long-term trend 2World shark attacks dipped in 2005, part of long-term trend 3Thin tough skin, slow-growing gills protect larval Antarctic fish 2Thin tough skin, slow-growing gills protect larval Antarctic fish 3
... demands of the routine trace metal analytical ... robust and simple to use instrumentation. The ... most challenging sample matrices found in the ... the toughest analytical challenges found in the ...
... Do you need to make your strain ... efficiency? Take advantage of Lucigen’s unrivalled expertise ... Competent Cell Service offers: Chemically ... efficiencies Fast turnaround ...
Procollagen type I C-terminal propeptide (human, PICP)...
... in Microarrays: Biomedical Photometrics Inc. (Waterloo, Ontario, ... Germany) have collaborated to develop a fluorescence ... The DNAscope AT is based on ... AT automatically reads up to six ArrayTubes ...
Biology Products: